Daniel Virnich is Chief Executive Officer of Starling Oncology, Inc. (STLN). The company reported total compensation of $1,934,930 for fiscal year 2025.
| Salary | $475,000 |
|---|---|
| Bonus | $212,729 |
| Stock awards | $1,235,001 |
| Option awards | $0 |
| Non-equity incentive plan | $0 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $12,200 |
| Total | $1,934,930 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Starling Oncology, Inc. filed April 30, 2026, accession 0001193125-26-197350.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Daniel Virnich this page | Chief Executive Officer | $1,934,930 |
| Yale Podnos | Chief Medical Officer | $775,905 |
| Robert Carter | Chief Financial Officer | $734,130 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Starling Oncology, Inc. compensation brief.
Daniel Virnich's compensation sits inside Starling Oncology, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.